1 Title: Endocrine disruption: where are we with hazard and risk assessment? 2 3 Running head: Hazard and risk assessment of endocrine disrupters 4 Katherine Coady*†, Peter Matthiessen‡, Holly M. Zahner§1, Jane Staveleyǁ; Daniel J. Caldwell#; 5 Steven L. Levine††, Leon Earl Gray Jr‡‡, Christopher J. Borgert§§ 6 7 † The Dow Chemical Company, Midland, MI, USA; 8 Telephone: 989-636-7423; Fax: 989-638-2425; e-mail:
[email protected]; ‡Independent 9 Consultant, Llanwrtyd Wells, UK; e-mail:
[email protected] ; § United States 10 Food and Drug Administration, Center for Veterinary Medicine, Rockville, MD, USA; email: 11
[email protected] ; ǁExponent Inc., Cary, NC, USA; email:
[email protected] ; 12 #Johnson & Johnson, New Brunswick, New Jersey, USA; email
[email protected] ; 13 ††Monsanto Company, St. Louis, MO, USA;email
[email protected]; ‡‡USEPA, 14 ORD, NHEERL, TAD, RTB. RTP, NC, USA; email:
[email protected] ; §§Applied 15 Pharmacology and Toxicology, Inc., and, Center for Environmental and Human Toxicology, 16 University of Florida, Gainesville, FL, USA; e-mail:
[email protected] 17 1The views presented in this article do not necessarily reflect those of the Food and Drug 18 Administration 19 * Corresponding Author: 20 Katherine Coady 21 The Dow Chemical Company, 1803 Building, Washington Street, Midland MI, USA, 48674. 22 Email address:
[email protected] PeerJ Preprints | https://doi.org/10.7287/peerj.preprints.2580v1 | CC0 Open Access | rec: 4 Nov 2016, publ: 23 24 ABSTRACT 25 Approaches to assessing endocrine disruptors (EDs) differ across the globe, with some 26 regulatory environments using a hazard-based approach, while others employ risk-based 27 analyses.